179 related articles for article (PubMed ID: 8012690)
1. A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys.
Roccon A; Marchionni D; Donat F; Segondy D; Cazaubon C; Nisato D
Br J Pharmacol; 1994 Jan; 111(1):145-50. PubMed ID: 8012690
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological study of SR 47436, a non-peptide angiotensin II AT1-receptor antagonist, in conscious monkeys.
Lacour C; Roccon A; Cazaubon C; Segondy D; Nisato D
J Hypertens; 1993 Nov; 11(11):1187-94. PubMed ID: 8301099
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
Siegl PK; Chang RS; Mantlo NB; Chakravarty PK; Ondeyka DL; Greenlee WJ; Patchett AA; Sweet CS; Lotti VJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):139-44. PubMed ID: 1625193
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist.
Cazaubon C; Gougat J; Bousquet F; Guiraudou P; Gayraud R; Lacour C; Roccon A; Galindo G; Barthelemy G; Gautret B
J Pharmacol Exp Ther; 1993 May; 265(2):826-34. PubMed ID: 8496828
[TBL] [Abstract][Full Text] [Related]
8. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
Bunting MW; Widdop RE
Br J Pharmacol; 1995 Dec; 116(8):3181-90. PubMed ID: 8719794
[TBL] [Abstract][Full Text] [Related]
9. Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
Morita O; Kushida H; Kunihara M
J Cardiovasc Pharmacol; 1995 Jun; 25(6):880-7. PubMed ID: 7564332
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.
Hilditch A; Hunt AA; Gardner CJ; Twissell DJ; Polley J; Travers A; Drew GM; Middlemiss D; Ross BC; Robertson MJ
Br J Pharmacol; 1994 Jan; 111(1):137-44. PubMed ID: 8012689
[TBL] [Abstract][Full Text] [Related]
11. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL
J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
[TBL] [Abstract][Full Text] [Related]
12. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
Leenen FH; Yuan B
Hypertension; 2001 Mar; 37(3):981-4. PubMed ID: 11244027
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.
Cirillo R; Renzetti AR; Cucchi P; Guelfi M; Salimbeni A; Caliari S; Castellucci A; Evangelista S; Subissi A; Giachetti A
Br J Pharmacol; 1995 Mar; 114(6):1117-24. PubMed ID: 7620700
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the haemodynamic effects of angiotensin II in conscious rats by AT2-receptor antagonists given after the AT1-receptor antagonist, EXP 3174.
Widdop RE; Gardiner SM; Kemp PA; Bennett T
Br J Pharmacol; 1992 Nov; 107(3):873-80. PubMed ID: 1472980
[TBL] [Abstract][Full Text] [Related]
15. Inhibition by BMS 186295, a selective nonpeptide AT1 antagonist, of adrenal catecholamine release induced by angiotensin II in the dog in vivo.
Martineau D; Yamaguchi N; Briand R
Can J Physiol Pharmacol; 1995 Apr; 73(4):459-64. PubMed ID: 7671188
[TBL] [Abstract][Full Text] [Related]
16. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
17. Effects of SC-52458, an angiotensin AT1 receptor antagonist, in the dog.
McMahon EG; Yang PC; Babler MA; Suleymanov OD; Palomo MA; Olins GM; Cook CS
Am J Hypertens; 1997 Jun; 10(6):671-7. PubMed ID: 9194514
[TBL] [Abstract][Full Text] [Related]
18. Effects of the angiotensin II receptor antagonist Losartan (DuP 753/MK 954) on arterial blood pressure, heart rate, plasma concentrations of angiotensin II and renin and the pressor response to infused angiotensin II in the salt-deplete dog.
MacFadyen RJ; Tree M; Lever AF; Reid JL
Clin Sci (Lond); 1992 Nov; 83(5):549-56. PubMed ID: 1335390
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
Belz GG; Butzer R; Kober S; Mutschler E
J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs.
Wong PC; Hart SD; Duncia JV; Timmermans PB
Eur J Pharmacol; 1991 Sep; 202(3):323-30. PubMed ID: 1748155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
